Dr James L Januzzi
Cardiologist, Massachusetts General Hospital. Prof of Medicine, Harvard Medical School

Management of Cardiovascular Risks of COVID-19 Patients


  • COVID-19 is a systemic disease caused by novel corona SARS-CoV2 virus. It causes inflammation, multi organ failure and in many cases cardiac stress and injury
  • COVID-19 is associated with abnormal hemotological, inflammatory, thrombotic and cardiac biomarkers
  • Abnormal levels of NT-proBNP and hs-Tn do not necessarily reflect Heart Failure and Acute Myocardial Infarction
  • Elevation in the cardiac biomarkers might help in clinical decision making including triage and management as well as imaging in COVID-19 patients

This webinar will shed light on how cardiac involvement due to acute myocarditis may occur in patients with COVID-19 without respiratory tract signs and symptoms of infection.  

By attending this webinar you will come away with a greater understanding of : 

  1. The potential mechanisms underlying cardiac biomarkers elevation with COVID-19 infections
  2. What biomarkers should be tested and when for the diagnosis of cardiovascular conditions in COVID-19 patients 
  3. Value of cardiac biomarkers in COVID-19 patient management 

Updates from Leading Experts

STRONG-HF: Post-discharge Heart Failure Management and Implementation of GDMT Heart Failure Therapy

Prof Alexandre Mebazaa shares the key results and highlights from the STRONG-HF study that assessed the safety, tolerability of optimization of guideline directed medical therapy. [...]


CANVAS study: NT-proBNP and CVD risk reduction

Can you give us a short description of the CANVAS program? The CANVAS program was a set of two trials, whose goal was to evaluate the role of an SGLT2...

1 July 2021
Dr James L Januzzi